Chinese medicine: Intends to relinquish the pre-emptive purchase right of 24% equity in Chongqing Yijian Health.

Chinese Medicine Announcement: The company has received a notice from Chongqing Yujian Shareholder Chongqing Yufu, intending to publicly list a transfer of 24% equity of Chongqing Yujian. The base price for the equity transfer is 2.206 billion yuan. The company has decided to waive its preemptive purchase right for the equity. It is currently uncertain whether the waiver of the preemptive purchase right constitutes a related party transaction, and it does not constitute a major asset restructuring situation. The 28th meeting of the ninth board of directors of the company approved the proposal, which still needs to be submitted for shareholder approval. The waiver of the preemptive purchase right will not result in any changes to the company's consolidated financial statements, nor will it decrease the company's ownership percentage in Chongqing Yujian. There is no situation that would harm the interests of the company or its shareholders, and it will not have a significant impact on the company's financial and operational conditions.